Ruxolitinib
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-RUXOLITINIB |
|---|---|
| Type | Drug |
| Aliases | JakafiJakaviРуксолітиніб |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-PMF DIS-PV |
| Sources | SRC-COMFORT-I-VERSTOVSEK-2012 SRC-NCCN-MPN-2025 SRC-RESPONSE-VANNUCCHI-2015 |
Drug Facts
| Class | JAK1/JAK2 inhibitor |
|---|---|
| Mechanism | Selective JAK1/JAK2 inhibitor. Blocks JAK-STAT signaling driven by JAK2 V617F (and CALR/MPL via JAK2 dimerization). Reduces splenomegaly + symptoms in MF/PV/ET; does not eliminate clone. Backbone of MF symptom-driven therapy. |
| Typical dosing | MF: 5-20 mg PO BID by baseline platelet count (plt 50-100K → 5 mg BID; 100-200K → 15 mg BID; >200K → 20 mg BID). Titrate by toxicity. PV (HU-resistant/intolerant): start 10 mg BID; titrate to Hct <45%. GVHD: 5-10 mg BID. |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Warnings
- Serious infections (TB, viral reactivation)
- Withdrawal syndrome on abrupt discontinuation (cytokine rebound, splenomegaly flare, sometimes life-threatening)
Notes
Established efficacy in symptomatic MF (COMFORT-I/II — improves spleen volume + symptoms + may extend OS in pooled analyses) and HU-resistant PV (RESPONSE — Hct + spleen response). NEVER abrupt-stop — taper over ≥1-2 weeks. HBV / HSV / TB screening before initiation. Anemia is predictable and usually managed with dose modification ± transfusion; momelotinib is preferred if anemia is dominant problem.
Used By
Regimens
REG-ALLOHCT-PMF- Allogeneic hematopoietic cell transplant for high-risk PMFREG-RUX-PMF- Ruxolitinib (PMF — symptomatic splenomegaly / constitutional symptoms)REG-RUX-PV- Ruxolitinib (PV — HU-resistant / intolerant)